1. Home
  2. JQC vs IRWD Comparison

JQC vs IRWD Comparison

Compare JQC & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

JQC

Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

N/A

Current Price

$4.76

Market Cap

705.1M

Sector

Finance

ML Signal

N/A

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

N/A

Current Price

$4.43

Market Cap

713.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JQC
IRWD
Founded
2003
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
705.1M
713.8M
IPO Year
N/A
2009

Fundamental Metrics

Financial Performance
Metric
JQC
IRWD
Price
$4.76
$4.43
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
612.6K
1.8M
Earning Date
01-01-0001
05-11-2026
Dividend Yield
11.13%
N/A
EPS Growth
N/A
1400.00
EPS
N/A
0.55
Revenue
N/A
$298,276,000.00
Revenue This Year
N/A
$57.95
Revenue Next Year
N/A
$4.39
P/E Ratio
N/A
$8.02
Revenue Growth
N/A
8.88
52 Week Low
$4.62
$1.05
52 Week High
$5.49
$5.78

Technical Indicators

Market Signals
Indicator
JQC
IRWD
Relative Strength Index (RSI) 44.08 55.93
Support Level $4.69 $3.85
Resistance Level $4.88 $4.53
Average True Range (ATR) 0.03 0.17
MACD -0.00 0.00
Stochastic Oscillator 16.67 83.16

Price Performance

Historical Comparison
JQC
IRWD

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Share on Social Networks: